8 reports

  • Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
  • Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Summary Lixte Biotechnology Holdings Inc (Lixte) is a clinical stage pharmaceutical company, which focuses on the discovery of novel drugs for the treatment of cancer and non-malignant diseases.It develops comprises two classes of drugs, namely, protein phosphatase inhibitors (PTase-i) designated as the LB-100 series; and...

  • Pharmaceutical
  • United States
  • Company
  • Corporate Finance
  • Lixte Biotechnology Holdings, Inc.
  • LIXTE BIOTECHNOLOGY HOLDINGS INC, PHARMACEUTICALS & HEALTHCARE, DEALS BY TYPE, 2012 TO YTD 2018
  • Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018

Lixte Biotechnology Holdings Inc (LIXT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities...

  • Pharmaceutical
  • United States
  • World
  • Company Financials
  • Lixte Biotechnology Holdings, Inc.
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Companies, H2 2018

It partners with other pharmaceutical companies for its drug development activities.

  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • Lixte Biotechnology Holdings, Inc.
  • Brain Ischemia - Products under Development by Companies
  • BRAIN ISCHEMIA - DORMANT PROJECTS (CONTD..1), H2 2016

Co., Ltd. ## ## ## ## ## ## Lixte Biotechnology Holdings, Inc. ## ## ## ## ## ## NeuroNascent, Inc. ## ## ## ## ## ## NeurOp, Inc ## ## ## ## ## ## Prolong Pharmaceuticals, LLC ## ## ## ## ## ## Sansho Co Ltd ## ## ## ## ##

  • Pharmaceutical
  • Turkey
  • United States
  • Company Operations
  • Lixte Biotechnology Holdings, Inc.
  • Ampio Pharmaceuticals Inc
  • Number of Products under Development by Companies, H1 2018

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2018 Summary According to the recently published report ’Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2018’; Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 8 molecules. Out...

  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • Lixte Biotechnology Holdings, Inc.
  • COHBAR INC

The molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Cardiovascular Disease
  • Gene Therapy
  • Pharmaceutical
  • Therapy
  • Lixte Biotechnology Holdings, Inc.
  • Septic Shock - Products under Development by Companies
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2016

In December 2012, Takeda Pharmaceutical Company Limited reported the preclinical study of BTZO-##, an active BTZO-## derivative, as a noble drug for sepsis.

  • Pharmaceutical
  • Therapy
  • United States
  • Company Operations
  • Lixte Biotechnology Holdings, Inc.
  • SP-9 - DRUG PROFILE
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2016

NOXXON PHARMA AG SEPTIC SHOCK - PIPELINE BY NOXXON PHARMA AG, H## 2016 OCTAPHARMA AG (OCTAPHARMA) IS A PHARMACEUTICAL COMPANY.

  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • Lixte Biotechnology Holdings, Inc.